These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11645532)

  • 1. Protection of human subjects; new drugs for investigational use; conforming amendments; final rule.
    U.S. Food and Drug Administration
    Fed Regist; 1984 Oct; 49(212):43637-8. PubMed ID: 11645532
    [No Abstract]   [Full Text] [Related]  

  • 2. Protection of human subjects; informed consent; standards for institutional review boards for clinical investigations; and clinical investigations which may be reviewed through expedited review procedures.
    U.S. Food and Drug Administration
    Fed Regist; 1981 Jan; 46(17):8942-80. PubMed ID: 11658611
    [No Abstract]   [Full Text] [Related]  

  • 3. Informed consent in the clinical research setting: experimentation on human subjects.
    Owens JF
    Med Trial Tech Q; 1987; 33(3):335-50. PubMed ID: 11653829
    [No Abstract]   [Full Text] [Related]  

  • 4. Protection of human subjects: technical amendments.
    U.S. Department of Health, Education, and Welfare
    Fed Regist; 1975 Mar; 40(50):11854-8. PubMed ID: 11664450
    [No Abstract]   [Full Text] [Related]  

  • 5. Proposed model federal policy for protection of human subjects; response to the First Biennial Report of the President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research.
    U.S. Office of Science and Technology Policy
    Fed Regist; 1986 Jun; 51(106):20204-17. PubMed ID: 11658721
    [No Abstract]   [Full Text] [Related]  

  • 6. Protection of human subjects; informed consent; proposed rule.
    U.S. Food and Drug Administration
    Fed Regist; 1995 Sep; 60(183):49086-103. PubMed ID: 11656433
    [No Abstract]   [Full Text] [Related]  

  • 7. The ethical review of medical research: a social movement to protect the interests of research subjects.
    Osborne LW
    Aust J Soc Issues; 1984 Aug; 19(3):155-60. PubMed ID: 11649620
    [No Abstract]   [Full Text] [Related]  

  • 8. IRB review of adverse events in investigational drug studies.
    Prentice ED; Gordon B
    IRB; 1997; 19(6):1-4. PubMed ID: 11656910
    [No Abstract]   [Full Text] [Related]  

  • 9. Annual review: observed deficiencies and suggested corrections.
    Adams MS; Conrad DA
    IRB; 1996; 18(6):1-4. PubMed ID: 11654743
    [No Abstract]   [Full Text] [Related]  

  • 10. Protecting research subjects after consent: the case for the "research intermediary.
    Reiser SJ; Knudson P
    IRB; 1993; 15(2):10-1. PubMed ID: 11651567
    [No Abstract]   [Full Text] [Related]  

  • 11. IRBs and pharmaceutical company funding of research.
    Jellinek MS; Levine RJ
    IRB; 1982 Oct; 4(8):9-10. PubMed ID: 11651693
    [No Abstract]   [Full Text] [Related]  

  • 12. Informed consent process is deemed "legally and ethically invalid" by witness.
    Maloney DM
    Hum Res Rep; 1995 Jan; 10(1):4-5. PubMed ID: 11660008
    [No Abstract]   [Full Text] [Related]  

  • 13. Federal policy for the protection of human subjects; notice and proposed rules.
    U.S. Office of Science and Technology Policy
    Fed Regist; 1988 Nov; 53(218):45660-82. PubMed ID: 11645617
    [No Abstract]   [Full Text] [Related]  

  • 14. Medical and psychological experimentation on California prisoners.
    Herch F; Flower R
    Univ Calif Davis Law Rev; 1974; 7():351-84. PubMed ID: 11661107
    [No Abstract]   [Full Text] [Related]  

  • 15. Neurobiological research involving human subjects: perspectives from the Office for Protection from Research Risks.
    Puglisi JT; Ellis GB
    Account Res; 1996; 4(3-4):261-5. PubMed ID: 11654521
    [No Abstract]   [Full Text] [Related]  

  • 16. Protection of human subjects.
    United States
    Code Fed Regul Shipping; 1982 Oct; Part 46, Sections 46.101 to 46.306():. PubMed ID: 11660819
    [No Abstract]   [Full Text] [Related]  

  • 17. Informed consent for human drugs and biologics; determination that informed consent is not feasible; interim rule and opportunity for public comment.
    U.S. Food and Drug Administration
    Fed Regist; 1990 Dec; 55(246):52814-7. PubMed ID: 11645686
    [No Abstract]   [Full Text] [Related]  

  • 18. Office for Protection from Research Risks (OPRR).
    Ellis GB
    Politics Life Sci; 1994 Aug; 13(2):271-3. PubMed ID: 11654650
    [No Abstract]   [Full Text] [Related]  

  • 19. Changing federal regulation of IRB's: the Commission's recommendations and the FDA's proposals.
    Levine RJ
    IRB; 1979 Mar; 1(1):1-3+. PubMed ID: 11662736
    [No Abstract]   [Full Text] [Related]  

  • 20. Two rules on expedited IRB reviews are final.
    Maloney DM
    Hum Res Rep; 1999 Jan; 14(1):3. PubMed ID: 11657557
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.